EUVIMEDEUVIMED entdecken
FallberichtOpen Access

Bridging Nonconsecutive Esketamine Weeks with Bupropion and Over-the-Counter Dextromethorphan

Richard Colby, Thomas Schwartz

Psychopharmacology Bulletin · 29.10.2026 · 56 (4) · 169-172

DOI: 10.64719/pb.21636 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Psychopharmacology Bulletin, online erschienen am 29.10.2026. Verfasst von Richard Colby und 1 weiteren Autor:innen. Beteiligte Einrichtung: Colby, BA, SUNY Upstate Medical University, Department of Psychiatry, Syracuse, NY. Hauptthemen laut MEDLINE: Bupropion, Dextromethorphan, Ketamine, Depressive Disorder, Treatment-Resistant. Die Arbeit nennt 5 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Frequent clinic visits required for maintenance intranasal (IN) esketamine therapy can limit treatment feasibility. Our case presents a 52-year-old woman with treatment-resistant depression (TRD) and bipolar II disorder (BD-II) who achieved sustained remission with weekly esketamine, but consistently experienced relapse of depressive symptoms when treatment intervals extended beyond 10 days. Her Patient Health Questionnaire-9 (PHQ-9) score decreased from 27 at baseline to 4 (±1) during maintenance treatment; however, with even a single delayed session, her PHQ-9 score could increase by as many as 8 points (from 4 to 12). To prevent relapse when she could not receive esketamine weekly, she began taking over-the-counter (OTC) dextromethorphan (DXM) and continued bupropion extended-release (XL), which she started prior to esketamine treatment. With 45 mg twice daily (BID) DXM and 450 mg daily bupropion XL, she was able to tolerate every-other-week administration of esketamine without depressive relapse. DXM and esketamine are both believed to function via antagonism of N-methyl-D-aspartate (NMDA) receptors. Bupropion is a competitive inhibitor of cytochrome P450 2D6 (CYP2D6), which is involved in the metabolism of DXM and maintenance of serum DXM concentration.1 As our patient was already taking bupropion XL, beginning OTC DXM was a low-cost option that we hoped would prevent relapse via continued NMDA antagonism in esketamine’s absence. To date, she is stable on a regimen of esketamine administration every 14 days, followed by 1 week of BID OTC DXM, to bridge esketamine doses and maintain NMDA antagonism, without return of depressive symptoms.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BupropionDextromethorphanKetamineDepressive Disorder, Treatment-ResistantNonprescription DrugsBipolar DisorderHumansFemaleMiddle AgedDrug Therapy, CombinationBridge TherapyDelayed-Action Preparations

Stichwörter der Autor:innen

N-methyl-D-aspartatebipolar disorderbupropioncombinationcytochrome P-450 CYP2D6 inhibitorsdepressive disorderdextromethorphandrug administration scheduledrug therapyketaminenonprescription drugsreceptorstreatment-resistant

Substanzen

BupropionDextromethorphanKetamineEsketamineNonprescription DrugsDelayed-Action Preparations

Autor:innen und Institutionen

  • Colby, BA, SUNY Upstate Medical University, Department of Psychiatry, Syracuse, NY.
  • Schwartz, MD, SUNY Upstate Medical University, Department of Psychiatry, Syracuse, NY.

Zitieren

APA

Colby, R., & Schwartz, T. (2026). Bridging Nonconsecutive Esketamine Weeks with Bupropion and Over-the-Counter Dextromethorphan. Psychopharmacology Bulletin, 56(4), 169-172. https://doi.org/10.64719/pb.21636

Vancouver

Colby R, Schwartz T. Bridging Nonconsecutive Esketamine Weeks with Bupropion and Over-the-Counter Dextromethorphan. Psychopharmacology Bulletin. 2026;56(4):169-172. doi:10.64719/pb.21636

BibTeX
@article{Colby2026,
  author = {Colby, Richard and Schwartz, Thomas},
  title = {Bridging Nonconsecutive Esketamine Weeks with Bupropion and Over-the-Counter Dextromethorphan},
  journal = {Psychopharmacology Bulletin},
  year = {2026},
  volume = {56},
  number = {4},
  pages = {169--172},
  doi = {10.64719/pb.21636}
}
Kostenlos starten →